FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2099-2100 May 13, 2004 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Stone, G. W. PubMed Citation

To the Editor: The optimal duration of clopidogrel therapy after percutaneous coronary intervention is the subject of ongoing debate. Stone et al. (Jan. 15 issue)¹ report the efficacy of paclitaxel-eluting stents as compared with bare-metal stents in reducing the rates of restenosis at nine months. Although clopidogrel therapy for six months was prescribed to prevent late thrombosis, the authors question the benefit of prolonged thienopyridine therapy in patients who have received a drug-eluting stent. Do the authors recommend a change in the duration of dual antiplatelet therapy for patients who have received these stents? As contemporary clinical practice suggests, drug-eluting . . . [Full Text of this Article]

This article has been cited by other articles:

• Koh, T.W (2004). Long-term clopidogrel therapy in the drug-eluting stent era: beyond CREDO and PCI-CURE. Eur Heart J 25: 1364-1364 [Full Text]